Clinical Trials
33 trialsA Study of 177Lu-PSMA-617 in People With Gliomas
Memorial Sloan Kettering Cancer Center
PREDICT
Alliance for Clinical Trials in Oncology
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
STARLiT
Case Comprehensive Cancer Center
COCORIVO
Centre Henri Becquerel
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
Case Comprehensive Cancer Center
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
M.D. Anderson Cancer Center
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
UPLIFT
University of California, San Francisco
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
LUTACT
University of California, San Francisco
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
(SEEtoTREAT)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Bullseye
Radboud University Medical Center
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Ankara University
LASER
Dana-Farber Cancer Institute
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
ReaLuP
Hospices Civils de Lyon
PROQURE-1
The Netherlands Cancer Institute
CaboLu
University of Utah
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Alliance for Clinical Trials in Oncology
STAMPEDE2
University College, London
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
PRODIGY-2
CHU de Quebec-Universite Laval
CATCH-177
Case Comprehensive Cancer Center
UpFrontPSMA
Peter MacCallum Cancer Centre, Australia